CAY10650
Based on 8 publication(s) in Google Scholar
CAY10650 is a highly potent cytosolic phospholipase A2α (cPLA2α) inhibitor with an IC50 value of 12 nM. CAY10650 suppresses lipid droplets formation and PGE2 secretion.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.0%
- No. CAS: 1233706-88-1
- Fòrmula: C28H25NO6
- Peso molecular:471.50
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Lipid Metabolism Compound Library
HY-L091
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
RNA Binding Bioactive Compound Library
HY-L248
Publications Citing Use of MedChemExpress (MCE) CAY10650
More- Exp Mol Med. 2023 Mar;55(3):574-586. [Abstract]
- Adv Sci (Weinh). 2024 Nov 26:e2411559. [Abstract]
- Adv Sci (Weinh). 2022 Sep 14;e2203995. [Abstract]
- Mater Today Bio. 2023 Dec 22:24:100919. [Abstract]
- JCI Insight. 2021 Oct 22;6(20):e151911. [Abstract]
- Korean J Physiol Pharmacol. 2021 Mar 1;25(2):159-166. [Abstract]
- Chemosphere. 2024 Jul 16:142885. [Abstract]
- Oxid Med Cell Longev. 2022 Jun 20;2022:5905374. [Abstract]
Customer Validation & Images
-
RT-PCR
-
WB
-
IF
-
Cell Migration/Invasion Assay
-
Histological Imaging/Staining
Ver todos los productos específicos de isoformas Phospholipase
More
Actividad biológica
CAY10650 (12 nM; 30 min; neutrophils) inhibits the expression of the phosphorylated cPLA2-α (p-cPLA2-α) in cells[1].
CAY10650 (12 nM; 2 h; neutrophils) inhibits PGE2 release in neutrophils[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Neutrophils
-
Concentration:12 nM
-
Incubation Time:30 minutes
-
Result:Inhibited cPLA2-α and inhibited the expression of the p-cPLA2-α.
-
Cell Line:Neutrophils
-
Concentration:12 nM
-
Incubation Time:2 hours
-
Result:Inhibited the PGE2 secretion and inhibited PGE2 realease.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Chinese hamsters with infected with parasite-laden contact lenses[1]
-
Dosage:50 μg/5 μL
-
Administration:Inject with topical eye-drop under the contact lens; three times a day for 6 days and topically on days 7 to 20 postinfection
-
Result:Reduced the severity of the keratitis and hasten the onset of resolution.
Had little mild inflammation and very few PMNs infiltration in the corneal stroma.
Chemical Information
-
No. CAS 1233706-88-1
-
Appearance Solid
-
Peso molecular 471.50
-
Fòrmula C28H25NO6
-
Color White to off-white
-
SMILES
O=C(CN1C(C=CC(C(O)=O)=C2)=C2C(C(C(C)C)=O)=C1)COC(C=C3)=CC=C3OC4=CC=CC=C4
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (8)
-
Journal Impact Factor
-
Most Recent
-
Exp Mol Med
NLRP3-dependent lipid droplet formation contributes to posthemorrhagic hydrocephalus by increasing the permeability of the blood-cerebrospinal fluid barrier in the choroid plexus. [Abstract]2023 Mar;55(3):574-586. PMID: 36869068 -
Adv Sci (Weinh)
2024 Nov 26:e2411559. PMID: 39587975
CAY10650 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Nov 26:e2411559. [Abstract]
Quantitative RT‐qPCR assessment of CPT1B expression in VSMCs pretreated with cPLA2 inhibitor CAY10650 (12 nmol L−1) for 3 h and subjected to 15% cyclic stretch (CS) or static (ST) for 12 h.
CAY10650 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Nov 26:e2411559. [Abstract]
Western blotting analysis of CPT1B protein levels in VSMCs pretreated with CAY10650 (12 nmol L−1) for 3 h and subjected to 15% CS or ST for 24 h.
CAY10650 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Nov 26:e2411559. [Abstract]
Immunofluorescent images of BODIPY FL C16 and mito‐tracker in VSMCs pretreated with CAY10650 (12 nmol L−1) and subjected to 15% CS or ST for 24 h.
CAY10650 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Nov 26:e2411559. [Abstract]
Cell migration in VSMCs pretreated with CAY10650 (12 nmol L−1) and subjected to 15% CS or ST for 24 h.
CAY10650 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Nov 26:e2411559. [Abstract]
Representative H&E staining of the cross sections of 6‐week VGs pretreated with DMSO or CAY10650 (12 nmol L−1) for 30 min at 37 °C before implantation.
-
Adv Sci (Weinh)
Geometric Constraints Regulate Energy Metabolism and Cellular Contractility in Vascular Smooth Muscle Cells by Coordinating Mitochondrial DNA Methylation. [Abstract]2022 Sep 14;e2203995. PMID: 36106364 -
Mater Today Bio
Cadherin-responsive hydrogel combined with dental pulp stem cells and fibroblast growth factor 21 promotes diabetic scald repair via regulating epithelial-mesenchymal transition and necroptosis. [Abstract]2023 Dec 22:24:100919. PMID: 38298888 -
JCI Insight
Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris. [Abstract]2021 Oct 22;6(20):e151911. PMID: 34491907 -
Korean J Physiol Pharmacol
NOX4/Src regulates ANP secretion through activating ERK1/2 and Akt/GATA4 signaling in beating rat hypoxic atria. [Abstract]2021 Mar 1;25(2):159-166. PMID: 33602886 -
Chemosphere
Indeno[1,2,3-cd]pyrene enhances the sensitivity of airway epithelial cells to ferroptosis and aggravates asthma. [Abstract]2024 Jul 16:142885. PMID: 39025314 -
Oxid Med Cell Longev
Cholecystokinin Octapeptide Promotes ANP Secretion through Activation of NOX4-PGC-1 α-PPAR α/PPAR γ Signaling in Isolated Beating Rat Atria. [Abstract]2022 Jun 20;2022:5905374. PMID: 35770043
Solvente y solubilidad
DMSO : 100 mg/mL (212.09 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Paloschi MV, et, al. Cytosolic phospholipase A2-α participates in lipid body formation and PGE2 release in human neutrophils stimulated with an L-amino acid oxidase from Calloselasma rhodostoma venom. Sci Rep. 2020 Jul 3;10(1):10976. [Content Brief]
[2]. Tripathi T, et, al. Role of phospholipase A₂ (PLA₂) inhibitors in attenuating apoptosis of the corneal epithelial cells and mitigation of Acanthamoeba keratitis. Exp Eye Res. 2013 Aug;113:182-91. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1209 mL | 10.6045 mL | 21.2089 mL | 53.0223 mL |
| 5 mM | 0.4242 mL | 2.1209 mL | 4.2418 mL | 10.6045 mL | |
| 10 mM | 0.2121 mL | 1.0604 mL | 2.1209 mL | 5.3022 mL | |
| 15 mM | 0.1414 mL | 0.7070 mL | 1.4139 mL | 3.5348 mL | |
| 20 mM | 0.1060 mL | 0.5302 mL | 1.0604 mL | 2.6511 mL | |
| 25 mM | 0.0848 mL | 0.4242 mL | 0.8484 mL | 2.1209 mL | |
| 30 mM | 0.0707 mL | 0.3535 mL | 0.7070 mL | 1.7674 mL | |
| 40 mM | 0.0530 mL | 0.2651 mL | 0.5302 mL | 1.3256 mL | |
| 50 mM | 0.0424 mL | 0.2121 mL | 0.4242 mL | 1.0604 mL | |
| 60 mM | 0.0353 mL | 0.1767 mL | 0.3535 mL | 0.8837 mL | |
| 80 mM | 0.0265 mL | 0.1326 mL | 0.2651 mL | 0.6628 mL | |
| 100 mM | 0.0212 mL | 0.1060 mL | 0.2121 mL | 0.5302 mL |
CAY10650 Related Classifications
HY-10801 Related Classifications
Powered by Bioz